(Total Views: 418)
Posted On: 10/29/2024 8:19:06 AM
Post# of 148863
Ram, the platform drug is even bigger. : )
We own the CCR5 iP to changing humanity
Napkin "value" on rolling 1.5b shares:
GSK @ $20 today:
$30b
Pfizer @ $29 today:
$35b
The safety profile of LL easily saves even more than those combined.
Our safety value affect is not to be overlooked.
Pfizer years back paid the highest buyout of $60b Pharmacia.
Inflation adjusted to today $115b.
The above scenarios is barely half the older $60b.
Pay us on HIV.
No spending "$60b" again.
Our shares adjust to their sp.
This kind of structure only costs them upfront the $4,$5,$6b cash or so on HIV?
Rolling "1.5b" shares frwd in exchange for a subsidiaries survival very deep into the future.
Licensing deals on the ones we don't retain.
I'd say would be an outstanding deal for a GSK/Pfizer.
We own the CCR5 iP to changing humanity
Napkin "value" on rolling 1.5b shares:
GSK @ $20 today:
$30b
Pfizer @ $29 today:
$35b
The safety profile of LL easily saves even more than those combined.
Our safety value affect is not to be overlooked.
Pfizer years back paid the highest buyout of $60b Pharmacia.
Inflation adjusted to today $115b.
The above scenarios is barely half the older $60b.
Pay us on HIV.
No spending "$60b" again.
Our shares adjust to their sp.
This kind of structure only costs them upfront the $4,$5,$6b cash or so on HIV?
Rolling "1.5b" shares frwd in exchange for a subsidiaries survival very deep into the future.
Licensing deals on the ones we don't retain.
I'd say would be an outstanding deal for a GSK/Pfizer.
(2)
(0)Scroll down for more posts ▼
